NCT06990347Completed
A Study on the Efficacy and Safety of IPyC for HER2+ MBC
A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined With Chemotherapy for HER2-positive Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 25 May 2025
Brief summary (registry, in English)
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 301 (actual)
- First submitted
- 18 May 2025
- Start date
- 1 Jul 2020
- Primary completion date
- 1 Aug 2024
- Lead sponsor
- Fujian Medical University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06990347
What you commit to
- Study type: Observational
- Participants enrolled: 301
- From 1 Jul 2020 to the primary completion date, 1 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with prior or current enrollment in interventional clinical trials for MBC
- patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib)
Other illness
- male patients or individuals with prior malignancy
Other
- patients who were lost to follow-up during the therapeutic process
Who the study is looking for
- patients who underwent a biopsy of the metastatic site and were confirmed as having MBC
- patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.